General MedicationsTOPICALStandard
ZORYVE
ROFLUMILAST
Standard Dose
0.15%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ZORYVE is listed in Drugs@FDA under application 215985 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient ROFLUMILAST Form and strength CREAM;TOPICAL - 0.15% Sponsor ARCUTIS Submission history Latest submission status date: 2025-10-04 00:00:00.
Structured Monograph
Clinical summary
Approval overview ZORYVE is listed in Drugs@FDA under application 215985 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ROFLUMILAST Form and strength CREAM;TOPICAL - 0.15% Sponsor ARCUTIS Submission history Latest submission status date: 2025-10-04 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.